1-deoxynojirimycin has been researched along with glycolipids in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butters, TD; Dwek, RA; Karlsson, GB; Neises, GR; Platt, FM | 1 |
| Butters, TD; Dwek, RA; Neises, GR; Platt, FM | 1 |
| Den Otter, W; Dullens, HF; Vliegenthart, JF; Voshol, H | 1 |
| Chavany, C; Jendoubi, M | 1 |
| Bieberich, E; Freischütz, B; Suzuki, M; Yu, RK | 1 |
| Füllekrug, J; Scheiffele, P; Simons, K | 1 |
| Fantini, J; Ganem, B; Hammache, D; Weber, KT | 1 |
| Butters, T; Dwek, R; Frendeus, B; Platt, F; Svanborg, C; Svensson, M | 1 |
| Butters, TD; Dwek, RA; Fleet, GW; Mellor, HR; Nolan, J; Pickering, L; Platt, FM; Wormald, MR | 1 |
| Futerman, AH; Jeyakumar, M; Lloyd-Evans, E; Pelled, D; Platt, FM; Riebeling, C | 1 |
| Aerts, JM; Boon, L; Bullens, D; Ceuppens, JL; Geboes, K; Kasran, A; Maerten, P; Rutgeerts, P; Shen, C; Van Assche, G | 1 |
| Butters, TD; Callaghan, R; Dwek, RA; Norris-Cervetto, E; Platt, FM | 1 |
| Patterson, MC; Platt, F | 1 |
| Alroy, J; d'Azzo, A; Kasperzyk, JL; Platt, FM; Seyfried, TN | 1 |
| Collmann, A; Compostella, F; De Libero, G; Facciotti, F; Michieletti, M; Mori, L; Panza, L; Schümann, J | 1 |
| Hughes, DA; Pastores, GM | 1 |
| Bryan, C; Crooks, A; Ding, W; Dingemanse, J; O'Donnell, P; Prociuk, M; Sikora, T; Stein, VM; Vanier, MT; Vite, CH; Walkley, SU | 1 |
| Benjamin, ER; Boudes, P; Brignol, N; Chang, HH; Fuller, M; Germain, DP; Giugliani, R; Hughes, DA; Khanna, R; Lockhart, DJ; Mehta, A; Nicholls, K; Sitaraman, SA; Soska, R; Valenzano, KJ; Young-Gqamana, B | 1 |
| Giese, AK; Grittner, U; Kolodny, E; Lackner, KJ; Lukas, J; Markoff, A; Mascher, H; Meyer, W; Rolfs, A; Saviouk, V; Wree, P | 1 |
| Cui, G; Huang, J; Wang, DW; Zeng, H; Zhou, C; Zhou, Q | 1 |
| McCafferty, EH; Scott, LJ | 1 |
| Mignani, R | 1 |
4 review(s) available for 1-deoxynojirimycin and glycolipids
| Article | Year |
|---|---|
Biology and potential strategies for the treatment of GM2 gangliosidoses.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Animals; beta-N-Acetylhexosaminidases; Bone Marrow Transplantation; Cats; Cell Transplantation; Child; Disease Models, Animal; Dogs; G(M2) Ganglioside; Genetic Therapy; Genetic Vectors; Glycolipids; HIV; Humans; Infant; Lysosomes; Mice; Mice, Knockout; Neurons; Phenotype; Point Mutation; Rats; Sandhoff Disease; Swine; Tay-Sachs Disease; Transplantation, Homologous | 1998 |
Therapy of Niemann-Pick disease, type C.
Topics: 1-Deoxynojirimycin; Animals; Cholesterol; Genetic Engineering; Genetic Therapy; Glycolipids; Humans; Neurons; Niemann-Pick Diseases; Stem Cell Transplantation | 2004 |
The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.
Topics: 1-Deoxynojirimycin; Animals; Autophagy; Calcium; Cell Membrane; Disease Models, Animal; DNA Mutational Analysis; Endoplasmic Reticulum; Enzyme Inhibitors; Enzyme Replacement Therapy; Gaucher Disease; Genetic Therapy; Glucosylceramidase; Glucosylceramides; Glycolipids; Homeostasis; Humans; Mice; Oxidative Stress; Proteostasis Deficiencies | 2010 |
Migalastat: A Review in Fabry Disease.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Approval; Enzyme Replacement Therapy; Fabry Disease; Female; Glycolipids; Humans; Male; Middle Aged; Mutation; Sphingolipids; Trihexosylceramides | 2019 |
18 other study(ies) available for 1-deoxynojirimycin and glycolipids
| Article | Year |
|---|---|
N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Cells, Cultured; Disease Models, Animal; Gaucher Disease; Glucosylceramidase; Glucosyltransferases; Glycolipids; Humans; Mice; Oligosaccharides; Structure-Activity Relationship | 1994 |
N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
Topics: 1-Deoxynojirimycin; Animals; Cell Line; Gaucher Disease; Glucosyltransferases; Glycolipids; Glycoside Hydrolase Inhibitors; Humans; Lysosomes; Macrophages; Mice; Models, Biological; Structure-Activity Relationship; Tumor Cells, Cultured | 1994 |
Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chains.
Topics: 1-Deoxynojirimycin; Carbohydrate Conformation; Carbohydrate Metabolism; Carbohydrates; Cell Membrane; Flow Cytometry; Glycoconjugates; Glycolipids; Glycosylation; Humans; Killer Cells, Natural; Lectins; Leukemia, Erythroblastic, Acute; Membrane Proteins; N-Acetylneuraminic Acid; Neoplasms; Neuraminidase; Sialic Acids; Trypsin; Tumor Cells, Cultured | 1993 |
Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells.
Topics: 1-Deoxynojirimycin; Animals; Apoptosis; Brain Neoplasms; Cell Death; Cell Division; Ceramides; Enzyme Inhibitors; Gaucher Disease; Glucosylceramides; Glucosyltransferases; Glycolipids; Mice; Morpholines; Neuroblastoma; Rats; Tumor Cells, Cultured | 1999 |
VIP36 localisation to the early secretory pathway.
Topics: 1-Deoxynojirimycin; Animals; Biological Transport; Biomarkers; Brefeldin A; Carrier Proteins; Cell Line; Chlorocebus aethiops; Coatomer Protein; Detergents; Dogs; Endoplasmic Reticulum, Smooth; Glycolipids; Glycoproteins; Glycosylation; Golgi Apparatus; HeLa Cells; Humans; Hybridomas; Kidney; Mannose-Binding Lectins; Membrane Glycoproteins; Membrane Proteins; Membrane Transport Proteins; N-Acetylglucosaminyltransferases; Protein Processing, Post-Translational; Recombinant Fusion Proteins; Solubility; Transfection; Vero Cells; Vesicular stomatitis Indiana virus; Viral Envelope Proteins | 1999 |
Synthesis of glycolipid analogues that disrupt binding of HIV-1 gp120 to galactosylceramide.
Topics: 1-Deoxynojirimycin; Anti-HIV Agents; Galactosylceramides; Glycolipids; HIV Envelope Protein gp120; Lipid Bilayers; Structure-Activity Relationship | 2000 |
Carbohydrate receptor depletion as an antimicrobial strategy for prevention of urinary tract infection.
Topics: 1-Deoxynojirimycin; Bacterial Adhesion; Escherichia coli; Escherichia coli Infections; Fimbriae, Bacterial; Glycolipids; Glycosphingolipids; Humans; Inflammation; Urinary Tract Infections | 2001 |
Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins.
Topics: 1-Deoxynojirimycin; Alkylation; Animals; Brain; Cattle; Cell Division; Cell Line; Enzyme Inhibitors; Glycolipids; Kinetics; Liver; Magnetic Resonance Spectroscopy; Mice; Models, Chemical; Time Factors; Tissue Distribution | 2002 |
Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
Topics: 1-Deoxynojirimycin; Adenosine Triphosphate; Animals; Blotting, Western; Brain; Calcium; Calcium-Transporting ATPases; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Enzyme Inhibitors; G(M2) Ganglioside; Gangliosides; Genotype; Glycolipids; Hippocampus; Kinetics; Lipid Metabolism; Mice; Mice, Transgenic; Microsomes; Neurons; Reverse Transcriptase Polymerase Chain Reaction; Sandhoff Disease; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Spectrophotometry; Thapsigargin; Time Factors | 2003 |
Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Anti-Inflammatory Agents; Antibodies; Body Weight; Colitis; Colon; Disease Models, Animal; Enzyme Inhibitors; Glycolipids; Haptens; Immunoglobulin G; Immunosuppressive Agents; Interferon-gamma; Interleukin-18; Male; Mice; Mice, Inbred C57BL; Oxazolone; Peroxidase; Trinitrobenzenesulfonic Acid | 2004 |
Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells.
Topics: 1-Deoxynojirimycin; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Ceramides; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Glucosamine; Glucosylceramides; Glucosyltransferases; Glycolipids; Humans; Imino Sugars; Lipids; Morpholines; Quinolines; Time Factors; Vinblastine | 2004 |
Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice.
Topics: 1-Deoxynojirimycin; Animals; Animals, Newborn; Brain Stem; Cerebellum; Chromatography, Thin Layer; Gangliosides; Gangliosidosis, GM1; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidation-Reduction; Sphingomyelins; Substrate Specificity | 2005 |
Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism.
Topics: 1-Deoxynojirimycin; Animals; Antigen Presentation; Antigens, CD1; Antigens, CD1d; beta-Galactosidase; CD4 Antigens; Dendritic Cells; Enzyme Inhibitors; Galactosylceramides; Globosides; Glycolipids; Humans; Lipid Metabolism; Lipid Metabolism Disorders; Liver; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Receptors, Antigen, T-Cell; Spleen; T-Lymphocyte Subsets; Thymus Gland; Trihexosylceramides; Vesicular Transport Proteins | 2007 |
Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C.
Topics: 1-Deoxynojirimycin; Animals; Antigens, CD; Area Under Curve; Brain; Case-Control Studies; Cat Diseases; Cats; Cell Survival; Cholesterol; Enzyme Inhibitors; Follow-Up Studies; Gangliosidoses, GM2; Microglia; Niemann-Pick Disease, Type C; Phagocytosis; Phenotype; Postmortem Changes; Purkinje Cells; Reactive Oxygen Species; Sphingomyelins; Sphingosine; Time Factors | 2012 |
Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Topics: 1-Deoxynojirimycin; Administration, Oral; alpha-Galactosidase; Animals; Fabry Disease; Glycolipids; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Reproducibility of Results; Sphingolipids; Sphingosine; Trihexosylceramides | 2013 |
Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Amino Acid Substitution; Fabry Disease; Glycolipids; Humans; Mutation; Phenotype; Protein Transport; Sphingolipids | 2013 |
Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease.
Topics: 1-Deoxynojirimycin; Adult; Aged; alpha-Galactosidase; Asian People; Base Sequence; Child; Exons; Fabry Disease; Female; Gene Expression; Glycolipids; HEK293 Cells; Humans; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Loss of Function Mutation; Male; Middle Aged; Pedigree; Phenotype | 2018 |
[The Fabry nephropathy: new insight in diagnosis, monitoring and treatment].
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Disease Progression; Enzyme Replacement Therapy; Fabry Disease; Female; Glomerulosclerosis, Focal Segmental; Glycolipids; Heterozygote; Humans; Isoenzymes; Kidney Diseases; Male; Oxidative Stress; Podocytes; Recombinant Proteins; Sex Factors; Sphingolipids; Trihexosylceramides | 2019 |